Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Aug 15;63(5):572-7.
doi: 10.1097/QAI.0b013e31829308f8.

No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana

Sajini Souda  1 , Simani Gaseitsiwe, Nathan Georgette, Kathleen Powis, Daisy Moremedi, Thato Iketleng, Jean Leidner, Claire Moffat, Anthony Ogwu, Shahin Lockman, Sikhulile Moyo, Mompati Mmalane, Rosemary Musonda, Joseph Makhema, Max Essex, Roger Shapiro
Affiliations
Randomized Controlled Trial

No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana

Sajini Souda et al. J Acquir Immune Defic Syndr. .

Abstract

Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission is unknown. The Mma Bana Study randomized treatment-naive pregnant women with CD4 ≥200 cells per cubic millimeter to receive either abacavir/zidovudine/lamivudine [triple nucleoside reverse transcriptase inhibitor (NRTI) arm] or lopinavir/ritonavir/zidovudine/lamivudine [protease inhibitor (PI) arm]. Drugs were discontinued after 6 months of breastfeeding. One month after discontinuation, 29 NRTI arm samples and 25 PI arm samples were successfully genotyped. No clinically significant antiretroviral resistance mutations were detected. Eight minor resistance mutations were found among 11 (20%) women (3 from NRTI arm and 8 from PI arm), occurring at similar frequencies to those reported in HIV-1 subtype C treatment-naive cohorts.

PubMed Disclaimer

Conflict of interest statement

No authors have a commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding).

References

    1. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, Switzerland: World Health Organization; 2010. - PubMed
    1. El-Sadr W, Lundgren JD, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. New Engl J Med. 2006;355(22):2283–2296. - PubMed
    1. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. The Lancet. 2006;367(9527):1981–1989. - PubMed
    1. Pogány K, Vanvalkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN) JAIDS Journal of Acquired Immune Deficiency Syndromes. 2007;44(4):395. - PubMed
    1. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Aids. 2007;21(8):965. - PubMed

Publication types

MeSH terms

Substances

Associated data